DSGN: Design Therapeutics, Inc.
Performance
DSGN +42.86%
Watchlist
Select an item
Summary
DSGN at a glance
DSGN returned +42.86% over the past year and -9.63% a year over five years. Its worst drop in that year was -39.34%, smaller than 38% of stocks on Redstone, and its Sharpe ratio of 0.81 beats 67% of stocks on Redstone. It pays no dividends.
Current Drawdown
-32.25%
Rolling Volatility
75.90%
Actions
Metrics
Risk Indicators
Alpha44.58%
Beta1.29x
Sharpe0.81
Sortino1.19
Omega1.16
Calmar1.09
Martin3.39
Profile
About DSGN
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $676M
- Listed
- Mar 2021
- Employees
- 55
- Headquarters
- Carlsbad, CA
- Website
- designtx.com
Comparisons